• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Recent treatment advances and practical management of hepatitis D virus.近期乙型肝炎病毒治疗进展及实际管理。
Clin Med (Lond). 2023 Jul;23(4):403-408. doi: 10.7861/clinmed.2022-0556. Epub 2023 Jun 23.
2
Hepatitis D: A Review.肝炎 D:综述。
JAMA. 2023 Dec 26;330(24):2376-2387. doi: 10.1001/jama.2023.23242.
3
New therapies for hepatitis delta virus infection.用于治疗 delta 肝炎病毒感染的新疗法。
Liver Int. 2021 Jun;41 Suppl 1:30-37. doi: 10.1111/liv.14838.
4
Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus.超越贝福替丁:治疗 delta 肝炎病毒的替代治疗选择。
J Viral Hepat. 2023 Apr;30 Suppl 1:33-38. doi: 10.1111/jvh.13789. Epub 2023 Jan 5.
5
Hepatitis D virus: Improving virological knowledge to develop new treatments.丁型肝炎病毒:增进病毒学知识以开发新疗法。
Antiviral Res. 2023 Jan;209:105461. doi: 10.1016/j.antiviral.2022.105461. Epub 2022 Nov 14.
6
Advances in hepatitis delta research: emerging insights and future directions.乙型肝炎 delta 病毒研究进展:新的认识与未来方向。
Sex Transm Infect. 2024 Jul 26;100(5):310-317. doi: 10.1136/sextrans-2023-056098.
7
Bulevirtide for HBV and HDV infections.布乐瑞韦肽治疗乙型肝炎病毒和丁型肝炎病毒感染。
Drugs Today (Barc). 2021 Jul;57(7):433-448. doi: 10.1358/dot.2021.57.7.3283861.
8
Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.HIV/乙型肝炎病毒合并感染中乙型肝炎 delta 病毒感染的流行病学、自然史和治疗。
Curr HIV/AIDS Rep. 2020 Aug;17(4):405-414. doi: 10.1007/s11904-020-00508-z.
9
What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options.治疗丁型肝炎病毒的前路在何方?:旧疗法与新选择。
Clin Liver Dis. 2023 Nov;27(4):985-995. doi: 10.1016/j.cld.2023.05.012. Epub 2023 Jul 14.
10
Management of autoimmune hepatitis induced by hepatitis delta virus.由乙型肝炎 delta 病毒引起的自身免疫性肝炎的管理。
World J Gastroenterol. 2024 Feb 28;30(8):799-805. doi: 10.3748/wjg.v30.i8.799.

引用本文的文献

1
Updates on Recent Advancements in Hepatitis D Virus Treatment.丁型肝炎病毒治疗的最新进展
Viruses. 2025 Aug 10;17(8):1100. doi: 10.3390/v17081100.
2
Hope on the horizon: Emerging therapies for hepatitis D.曙光在前:丁型肝炎的新兴疗法
World J Hepatol. 2025 Jun 27;17(6):107963. doi: 10.4254/wjh.v17.i6.107963.
3
Current perspectives of viral hepatitis.病毒性肝炎的研究现状。
World J Gastroenterol. 2024 May 14;30(18):2402-2417. doi: 10.3748/wjg.v30.i18.2402.

本文引用的文献

1
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.布列韦肽联合替诺福韦酯治疗乙型肝炎病毒和丁型肝炎病毒合并感染患者的安全性和有效性(MYR202):一项多中心、随机、平行组、开放标签的2期试验。
Lancet Infect Dis. 2023 Jan;23(1):117-129. doi: 10.1016/S1473-3099(22)00318-8. Epub 2022 Sep 13.
2
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.在伴有 HDV 相关代偿性肝硬化和临床显著门静脉高压的患者中,蓝病毒替单独治疗 48 周。
J Hepatol. 2022 Dec;77(6):1525-1531. doi: 10.1016/j.jhep.2022.07.016. Epub 2022 Aug 13.
3
Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies.布立伏定联合或不联合聚乙二醇干扰素α治疗代偿期慢性丁型肝炎患者:从临床试验到真实世界研究
J Hepatol. 2022 Nov;77(5):1422-1430. doi: 10.1016/j.jhep.2022.06.010. Epub 2022 Jun 22.
4
Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection.在慢性乙型和丁型肝炎合并感染的真实世界患者中,布列韦迪与替诺福韦酯联用的疗效和安全性
Pathogens. 2022 Apr 27;11(5):517. doi: 10.3390/pathogens11050517.
5
Combination of Novel Therapies for HDV.新型药物联合治疗丁型肝炎。
Viruses. 2022 Jan 28;14(2):268. doi: 10.3390/v14020268.
6
Novel Therapies of Hepatitis B and D.乙型和丁型肝炎的新型疗法
Microorganisms. 2021 Dec 17;9(12):2607. doi: 10.3390/microorganisms9122607.
7
A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.洛那法尼联合ritonavir 与或不联合干扰素α治疗慢性 delta 肝炎的 2 期剂量探索研究。
Hepatology. 2022 Jun;75(6):1551-1565. doi: 10.1002/hep.32259. Epub 2021 Dec 23.
8
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.长达 3 年的单用布乐瑞肽治疗 HDV 相关肝硬化患者的安全性和有效性。
J Hepatol. 2022 Feb;76(2):464-469. doi: 10.1016/j.jhep.2021.10.012. Epub 2021 Oct 23.
9
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.2021 年的丁型肝炎病毒:病毒学、免疫学和针对难治性疾病的新治疗方法。
Gut. 2021 Sep;70(9):1782-1794. doi: 10.1136/gutjnl-2020-323888. Epub 2021 Jun 8.
10
Experimental Drugs for the Treatment of Hepatitis D.治疗丁型肝炎的实验性药物
J Exp Pharmacol. 2021 Apr 16;13:461-468. doi: 10.2147/JEP.S235550. eCollection 2021.

近期乙型肝炎病毒治疗进展及实际管理。

Recent treatment advances and practical management of hepatitis D virus.

机构信息

Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK.

Liver Unit, Queen, Elizabeth Hospital Birmingham, Birmingham, UK.

出版信息

Clin Med (Lond). 2023 Jul;23(4):403-408. doi: 10.7861/clinmed.2022-0556. Epub 2023 Jun 23.

DOI:10.7861/clinmed.2022-0556
PMID:37353306
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10541033/
Abstract

Hepatitis D virus (HDV), also referred to as hepatitis delta virus, is the smallest virus capable of causing human disease. It is unable to replicate on its own and can only propagate in the presence of hepatitis B virus (HBV). Infection with both HBV and HDV frequently results in more severe disease than HBV alone, with higher instances of cirrhosis, liver failure and hepatocellular carcinoma (HCC). Thus, there is a need for effective treatment for HDV; however, currently approved treatment options are very limited both in terms of their efficacy and availability. This makes the management of HDV a challenge for physicians. In this review, we look at the background, diagnosis and treatment of HDV, informed by our hospital data, to set out the optimal management of HDV; we also explore novel treatment options for this disease.

摘要

丁型肝炎病毒(HDV),亦称δ肝炎病毒,是能够导致人类疾病的最小病毒。它不能自行复制,只能在乙型肝炎病毒(HBV)存在的情况下进行繁殖。感染 HBV 和 HDV 通常比单独感染 HBV 导致更严重的疾病,肝硬化、肝功能衰竭和肝细胞癌(HCC)的发生率更高。因此,需要对 HDV 进行有效的治疗;然而,目前批准的治疗方案在疗效和可及性方面都非常有限。这使得 HDV 的管理对医生来说是一个挑战。在这篇综述中,我们根据我们医院的数据,探讨了 HDV 的背景、诊断和治疗,以制定 HDV 的最佳管理方案;我们还探索了这种疾病的新的治疗选择。